Quanterix Corporation filed a Form 8-K on November 18, 2026, disclosing the resignation of President and Chief Executive Officer Everett Cunningham and the appointment of James Gute as Interim President and Chief Executive Officer, both effective the same date.
Key Highlights
- CEO departure: Everett Cunningham resigned as President, CEO, and Board member of Quanterix Corporation, effective November 18, 2026, to accept another opportunity.
- No disagreements cited: According to the filing, Cunningham's departure "is not related to any disagreements with the Company on any matter relating to its operations, policies, practices (financial or otherwise) or any issues regarding financial disclosures, accounting, or legal matters."
- Transition support: Cunningham will remain available to assist with an orderly transition of responsibilities through December 11, 2026.
- Interim appointment: James Gute, the Company's Chief Commercial Officer, was appointed Interim President and CEO effective November 18, 2026, pending a permanent search.
- Interim compensation: Gute will be paid a salary of $750,000 on an annualized basis while fulfilling the interim role.
- Gute's background: Age 52, Gute joined Quanterix in August 2026 and previously served at Exact Sciences (now Abbott Laboratories, Cancer Diagnostics) and GE Healthcare, where he held roles over 18 years.
Cunningham Exits Quanterix as Gute Steps Into Interim CEO Role
Quanterix Corporation (NASDAQ:QTRX) disclosed in an 8-K filed November 18, 2026, that Everett Cunningham has resigned as President and Chief Executive Officer and as a member of the Board of Directors, with both departures taking effect immediately. The filing states that Cunningham has accepted another opportunity and that the departure is unrelated to any disagreements over company operations, policies, practices, financial disclosures, accounting, or legal matters. He is expected to remain available through December 11, 2026, to support the transition of his responsibilities.
The Board has appointed James Gute, currently serving as the Company's Chief Commercial Officer, to serve as Interim President and Chief Executive Officer while a permanent search is conducted. According to the filing, Gute, age 52, joined Quanterix in August 2026. Prior to that, he served as Senior Vice President and Commercial Manager, General Screening at Exact Sciences (now Abbott Laboratories, Cancer Diagnostics) from August 2024 to August 2026, and as General Manager, Western Region at the same organization from January 2022 to August 2024. Before those roles, he held several positions at GE Healthcare over 18 years, most recently as President of the North Central Region.
The filing states that Gute and his immediate family members are not party to any related party transactions requiring disclosure under Item 404(a) of Regulation S-K, and that there is no family relationship between Gute and any of the Company's directors or executive officers. In connection with the interim appointment, Gute will receive an annualized salary of $750,000. The Company also issued a press release on November 18, 2026, attached as Exhibit 99.1 to the filing.
What Was Disclosed
Quanterix Corporation reported the immediate resignation of its President and CEO Everett Cunningham and his replacement on an interim basis by Chief Commercial Officer James Gute, who will receive an annualized salary of $750,000 while serving in the role.



Please wait processing your request...